NCT01882179View on ClinicalTrials.gov

Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size

PHASE3CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
ST-elevation Myocardial Infarction
Interventions
DRUG

Mineralocorticoid receptor antagonist potassium-canrenoate

DRUG

placebo

Trial Locations (4)

SS16 5NL

Cardiothoracic Center - Basildon and Thurrock University Hospitals, Basildon

E2 9JX

London Chest Hospital, London

W1G 8PH

Heart Hospital London, London

Unknown

Leeds Genereal Infirmary, Leeds

All Listed Sponsors
collaborator

British Heart Foundation

OTHER

lead

University College, London

OTHER

NCT01882179 - Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size | Biotech Hunter | Biotech Hunter